APLN and atherosclerosis: Clinical evidence indicating unbalanced adipokine profile (decreased serum adiponectin, apelin, omentin-1 levels and increased serum leptin, resistin, chemerin concentrations) in coronary atherosclerosis disease patients [100–105], further highlight the importance of adipokines as biomarkers for atherosclerosis.